

## Elevated hematocrit enhances platelet accumulation following vascular injury

**Running title:** Elevated hematocrit promotes arterial thrombosis

Bethany L. Walton<sup>1</sup>, Marcus Lehmann<sup>2</sup>, Tyler Skorczewski<sup>3</sup>, Lori A. Holle<sup>1</sup>, Joan D. Beckman<sup>4</sup>, Jeremy A. Cribb<sup>5</sup>, Micah J. Mooberry<sup>4</sup>, Adam R. Wufsus<sup>2</sup>, Brian C. Cooley<sup>6</sup>, Jonathan W. Homeister<sup>1</sup>, Rafal Pawlinski<sup>4,6</sup>, Michael R. Falvo<sup>5</sup>, Nigel S. Key<sup>4,6</sup>, Aaron L. Fogelson<sup>7</sup>, Keith B. Neeves<sup>2,8</sup>, Alisa S. Wolberg<sup>1,6</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>2</sup>Department of Chemical and Biological Engineering, Colorado School of Mines, Golden, CO

<sup>3</sup>Department of Mathematics and Statistics, Cornell College, Mount Vernon, Iowa

<sup>4</sup>Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, NC

<sup>5</sup>Department of Physics and Astronomy, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>6</sup>McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>7</sup>Departments of Mathematics and Bioengineering, University of Utah, Salt Lake City, Utah

<sup>8</sup>Pediatrics, University of Colorado-Denver, Aurora, CO

Address correspondence to:

Alisa S. Wolberg, Ph.D.  
Department of Pathology and Laboratory Medicine  
University of North Carolina at Chapel Hill  
819 Brinkhous-Bullitt Building, CB #7525  
Chapel Hill, NC 27599-7525  
Phone: (919) 962-8943; Fax: (919) 966-6718  
Email: [alisa\\_wolberg@med.unc.edu](mailto:alisa_wolberg@med.unc.edu)

**Abstract word count:** 237

**Manuscript word count (Introduction, Methods, Results, Discussion):** 4052

**Figures:** 6 (2 black & white, 4 color)

**Tables:** 2

**References:** 61

**Scientific category:** Thrombosis and Hemostasis

## **KEY POINTS**

- 1) Elevated hematocrit independently promotes arterial thrombus formation.
- 2) During arterial thrombosis, elevated hematocrit enhances platelet accumulation at the site of vessel injury.

## ABSTRACT

Red blood cells (RBCs) demonstrate procoagulant properties *in vitro*, and elevated hematocrit is associated with reduced bleeding and increased thrombosis risk in humans. These observations suggest RBCs contribute to thrombus formation. However, effects of RBCs on thrombosis are difficult to assess because humans and mice with elevated hematocrit typically have co-existing pathologies. Using an experimental model of elevated hematocrit in healthy mice, we measured effects of hematocrit in two *in vivo* clot formation models. We also assessed thrombin generation, platelet-thrombus interactions, and platelet accumulation in thrombi *ex vivo*, *in vitro*, and *in silico*. Compared to controls, mice with elevated hematocrit (RBC<sup>HIGH</sup>) formed thrombi at a faster rate and had a shortened vessel occlusion time. Thrombi in control and RBC<sup>HIGH</sup> mice did not differ in size or fibrin content, and there was no difference in levels of circulating thrombin-antithrombin complexes. *In vitro*, increasing the hematocrit increased thrombin generation in the absence of platelets; however, this effect was reduced in the presence of platelets. *In silico*, direct numerical simulations of whole blood predicted elevated hematocrit increases the frequency and duration of interactions between platelets and a thrombus. When human whole blood was perfused over collagen at arterial shear rates, elevating the hematocrit increased the rate of platelet deposition and thrombus growth. These data suggest RBCs promote arterial thrombosis by enhancing platelet accumulation at the site of vessel injury. Maintaining a normal hematocrit may reduce arterial thrombosis risk in humans.

## KEYWORDS

Erythrocytes, arterial thrombosis, platelet margination, thrombin-antithrombin complexes, tissue factor, collagen, erythrocytosis

## INTRODUCTION

Red blood cells (RBCs) are the most abundant cells in blood. Normal RBC numbers range from 4.2- to  $6.1 \times 10^9$ /mL in humans; males have slightly higher levels than females. RBCs are primarily known for their hemoglobin-mediated role in oxygen transport. However, a growing body of evidence suggests RBCs have biochemical and biophysical properties that may contribute to thrombosis. First, RBCs are the principal determinant of blood viscosity, an established risk factor for thrombosis.<sup>1</sup> Blood viscosity increases non-linearly with increased hematocrit.<sup>2,3</sup> Consequently, elevated hematocrit, even within a clinically-relevant range (40-60%), increases blood viscosity at both arterial and venous shear rates.<sup>4</sup> Second, simulations and experimental studies using models of intact (uninjured) arteries suggest RBCs enrich the near-wall region with platelets (margination).<sup>5,6</sup> Third, RBCs enhance platelet  $\alpha_{IIb}\beta_3$  activation and P-selectin exposure in response to agonists (e.g., collagen, thrombin).<sup>7-9</sup> Fourth, platelet accumulation on excised subendothelial matrices increases with increasing hematocrit (10-70%) at arterial shear rates.<sup>10</sup> Finally, RBCs and RBC-derived microvesicles have exposed phosphatidylserine on their outer membrane and can support thrombin generation *in vitro*.<sup>11-18</sup> Overall, these studies support the hypothesis that elevated RBCs can directly enhance thrombosis. However, which, if any, of these pathways contribute to thrombosis *in vivo* is unclear. Determining the contribution of RBCs to coagulation *in vivo* is clinically important because elevated hematocrit is an independent risk factor for cardiovascular disease and cardiovascular-related deaths.<sup>19-24</sup> Thus, increased understanding of the relationship between hematocrit and thrombosis is needed to guide clinical strategies.

Previous studies in animal models have examined the pathophysiologic effects of elevated hematocrit in JAK 2<sup>V617F</sup>-induced polycythemia vera (PV) or erythrocytosis mediated by endogenous overproduction of erythropoietin.<sup>25-28</sup> Findings from these studies expose complex, and sometimes discordant, effects of hematocrit on coagulation and failed to reveal a clear relationship between hematocrit and thrombosis. For example, a mouse model of JAK 2<sup>V617F</sup>-induced PV exhibits a prothrombotic phenotype following FeCl<sub>3</sub> injury to mesenteric vessels, but an apparent paradoxical increase in bleeding following tail transection.<sup>27</sup> However, these mice are deficient in platelet GPVI and have reduced plasma von Willebrand factor multimers<sup>27</sup>, making it difficult to assess the contribution of elevated hematocrit to thrombosis. Mice genetically-engineered to overexpress human erythropoietin also show increased bleeding in a tail bleeding model.<sup>26</sup> However, these animals have a markedly increased hematocrit (80-85%) not seen in humans, and the increased bleeding may be explained by a

reduction in plasma volume.<sup>26</sup> Erythropoietin-infused mice with less dramatically elevated hematocrit ( $60\pm 5.5\%$ ) do not differ from controls in a  $\text{FeCl}_3$ -induced mesentery thrombosis model.<sup>27</sup> However, since erythropoietin has downstream effects on multiple cell types<sup>29-32</sup>, it is also difficult to assess specific effects of elevated hematocrit with this approach.

Herein, we analyzed the effect of RBCs on thrombus formation in an experimental model of elevated hematocrit in healthy mice. Compared to controls, increased hematocrit shortened the time to carotid artery occlusion and shortened the clotting time following tail transection. *Ex vivo*, *in silico*, and *in vitro* analyses suggest this effect did not stem from increased thrombin generation, but rather, was associated with increased frequency of platelet-thrombus interactions, leading to accelerated platelet accumulation and more rapid thrombus growth.

## METHODS

**Proteins and Materials** are detailed in Supplemental Materials.

**Mouse model of elevated hematocrit.** Procedures were approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee. Whole blood was collected from healthy, anesthetized 6-to-8-week old male and female C57Bl/6 mice via inferior vena cava venipuncture into 3.2% sodium citrate (10% v/v, final). Blood was centrifuged (150xg, 10 min) to separate RBCs from platelet-rich plasma (PRP). RBCs were re-suspended in sterile citrate-glucose-saline (1.29 mM sodium citrate, 3.33 mM glucose, 124 mM NaCl, pH 7.2) and washed by centrifugation (3X 400xg, 5 min). Washed RBCs were re-suspended in sterile HEPES-buffered saline (20 mM N-2-hydroxyethylpiperazine-*N'*-2-ethane-sulfonic acid, 150 mM NaCl, pH 7.4 [HBS]) and centrifuged (400xg, 10 min) to pack RBCs. RBCs were counted (HV950FS Hemavet cell counter, Drew Scientific, Dallas, TX) and the hematocrit adjusted to 70%. Recipient 6-to-8-week old male C57Bl/6 mice were anesthetized, injected with packed RBCs via retro-orbital plexus (~250  $\mu$ L), and allowed to recover. After 24 hours, blood was drawn from the inferior vena cava for hematological analysis or animals were subjected to thrombosis models (separate mice). Methods for blood smears, flow cytometry, thrombin-antithrombin complex (TATc), and whole blood viscosity measurements are detailed in Supplemental Materials.

**Mouse models of clotting.** The FeCl<sub>3</sub> injury model was performed as described.<sup>33,34</sup> Briefly, 6-to-8-week old male C57Bl/6 mice were anesthetized. The right common carotid artery was exposed, dried, and treated with FeCl<sub>3</sub> (10%, 0.5x0.5-mm filter paper, 2 min). Blood flow was monitored auditorily by Doppler ultrasonic flow probe. Time to vessel occlusion (TTO) was the time between FeCl<sub>3</sub> administration and lack of flow for 1 min. Doppler tracings recorded for a subset of mice were used to determine thrombus onset time (inflection point when blood flow began to decrease and resulted in vessel occlusion) and thrombus formation rate (maximum rate of decrease in blood flow [ $\text{min}^{-1}$ ] following the thrombus onset time). Mice that did not experience carotid occlusion were omitted from onset and rate analysis because they did not form defined thrombi.

Tail transection assays were performed as described in Supplemental Materials.

**Phlebotomy.** Blood was drawn from healthy, consenting human donors in accordance with the Declaration of Helsinki and University of North Carolina at Chapel Hill and University of Colorado at Boulder Institutional Review Boards. Donors had not ingested aspirin for  $\geq 5$  days prior to phlebotomy. Blood was collected via antecubital venipuncture into 0.105 M sodium citrate, pH 5.5 (10% v/v, final).

**Thrombin generation in reconstituted human whole blood.** Thrombin generation was measured using whole blood calibrated automated thrombography<sup>15</sup> as detailed in Supplemental Materials.

**Computational modeling.** Simulations of human whole blood flow driven by a pressure gradient through a 50- $\mu\text{m}$  channel were conducted with a custom Lattice-Boltzmann Immersed Boundary method code.<sup>35-37</sup> For each simulation, the channel was partially occluded by a preformed thrombus of specified shape and size. The pressure gradient was set to achieve a wall shear rate of approximately  $1100 \text{ sec}^{-1}$ . At a sequence of times, the fluid velocity field was computed, accounting for mechanical forces generated by numerous deformable RBCs and a smaller number of less deformable platelets. Rheological properties of the RBC suspension emerge from the simulations. Trajectories through space of 700 points on each RBC surface and 100 points on each platelet surface were tracked as functions of time, thus determining each cell's location, orientation, and deformation. Simulations were conducted for hematocrits of 40% and 60%, for small (base 44  $\mu\text{m}$ , top surface 34  $\mu\text{m}$ , height 7.2  $\mu\text{m}$ ) and large (base 44  $\mu\text{m}$ , top surface 24  $\mu\text{m}$ , height 11.5  $\mu\text{m}$ ) thrombi. For each case, a RBC distribution at statistical equilibrium was pre-computed and then 10 flow simulations were carried out starting with this RBC distribution and with a platelet placed at a randomly-chosen position in the near-wall RBC-depleted zone 14-44  $\mu\text{m}$  upstream of the thrombus. Simulation results were processed using custom MATLAB scripts.

**Microfluidic model with reconstituted whole blood.** Fibrillar collagen (500  $\mu\text{g}/\text{mL}$ ) was patterned in 200- $\mu\text{m}$  spots onto clean glass, as described.<sup>38</sup> Human whole blood was separated into PRP and RBCs by centrifugation (200xg, 20 min) and reconstituted to 45 and 60% hematocrits. Reconstituted aliquots were labeled with DiOC6 and Alexa Fluor 555-labeled fibrinogen (1  $\mu\text{M}$  and 56  $\mu\text{g}/\text{mL}$ , final concentrations, respectively) at 37°C for 15 min. Labeled blood was recalcified with buffer (75 mM  $\text{CaCl}_2$  and 37 mM  $\text{MgCl}_2$  in HBS, 9:1 flow rate ratio) using a continuous microfluidic mixer<sup>39</sup> upstream of a custom PDMS flow chamber (height 51  $\mu\text{m}$ , width 500  $\mu\text{m}$ ), and perfused over collagen ( $750 \text{ sec}^{-1}$ ,

15 min). Final hematocrits were 41% and 54%. Total thrombus size, fibrin formation, and platelet accumulation were captured by relief contrast and epifluorescence microscopy (Olympus IX81, 20X NA=0.45,  $\lambda_{\text{ex}}/\lambda_{\text{em}}$  475/505, 545/580, at 6 frames/min). Thrombus area fraction, fibrin formation, and platelet accumulation were measured as described.<sup>39</sup>

**Statistical methods.** Descriptive statistics (mean, median, standard deviation [SD]) were calculated. Groups were compared using Student's *t*-tests (normally distributed data using Lilliefors test for normality) or Wilcoxon-Mann-Whitney rank sum tests (non-normally distributed data) in Kaleidagraph version 4.1.3 (Synergy Software, Reading, PA). For viscosity experiments, viscosity and shear rate were logarithmically-transformed and then analyzed using a linear model. For microfluidics experiments, data were analyzed by paired *t*-test.



## RESULTS

**Experimental model of elevated hematocrit in mice.** To study the effect of elevated hematocrit *in vivo*, we used an experimental model in which we raised the hematocrit in healthy mice with fresh, washed RBCs from healthy donor mice. Complete blood counts showed RBC<sup>HIGH</sup> mice had an elevated hematocrit compared to control mice ( $P < 0.0001$ , Figure 1A, Table I). Levels of neutrophils and monocytes were similar in controls and RBC<sup>HIGH</sup> mice (Figure 1B-C, Table I). Platelet levels were slightly lower in RBC<sup>HIGH</sup> mice compared to controls (Figure 1D, Table I), but remained in the normal range. Blood smears showed normal morphology of washed RBCs (Figure 1E, left) and RBCs from control mice (Figure 1E, middle) and RBC<sup>HIGH</sup> mice (Figure 1E, right). Consistent with prior reports<sup>11,12,40,41</sup>, less than 1% of packed RBCs or circulating RBCs in control or RBC<sup>HIGH</sup> mice had exposed phosphatidylserine (Figure 1F). Plasmas isolated from control and RBC<sup>HIGH</sup> mice had similar circulating TATc ( $3.7 \pm 0.5$  and  $2.2 \pm 1.3$  ng/mL, respectively, mean  $\pm$  SD). As expected, whole blood from RBC<sup>HIGH</sup> mice was more viscous than whole blood from control mice over a range of shear rates (30-2300  $\text{sec}^{-1}$ , Figure 1G), and blood flow was slightly, though non-significantly, slower in RBC<sup>HIGH</sup> mice versus controls ( $1457.9 \pm 295.0$  versus  $2177.9 \pm 1230.6$  Hz, respectively, mean  $\pm$  SD). Together, these data establish a model of elevated hematocrit in otherwise healthy mice.

**Compared to controls, RBC<sup>HIGH</sup> mice have a faster time to artery occlusion and shorter tail bleeding time.** To determine the effect of elevated hematocrit on thrombosis, we first subjected control and RBC<sup>HIGH</sup> mice to the FeCl<sub>3</sub>/carotid artery thrombosis model. Compared to controls, RBC<sup>HIGH</sup> mice had a significantly shorter TTO ( $13.2 \pm 6.6$  versus  $5.3 \pm 0.9$  min, respectively, mean  $\pm$  SD; 12.7(13.9) versus 5.4(2.6) min, respectively, median(range),  $P < 0.001$ , Figure 2A). At the time when 50% of control mice had complete vessel occlusion, 100% of RBC<sup>HIGH</sup> mice had an occluded vessel. A separate experiment in which control mice were compared to mice injected with RBC wash supernatant (RBC<sub>wash</sub>) showed no difference in TTO ( $10.9 \pm 7.1$  versus  $8.8 \pm 5.7$  min for control and RBC<sub>wash</sub> mice, respectively, mean  $\pm$  SD; 7.1(15) versus 7.3(15.8) min, respectively, median(range),  $P = 0.87$ ,  $N = 6/\text{group}$ ), indicating the shortened TTO in RBC<sup>HIGH</sup> mice was not caused by RBC releasates during RBC preparation. Doppler tracings indicated the thrombus onset time for RBC<sup>HIGH</sup> mice was not significantly different from control mice (Figure 2B), but the thrombus formation rate was significantly faster ( $0.020 \pm 0.006$  versus  $0.012 \pm 0.003$   $\text{min}^{-1}$ , respectively, mean  $\pm$  SD,  $P < 0.05$ , Figure 2C).

To test whether elevated hematocrit promoted clotting in a second *in vivo* model, we subjected control and RBC<sup>HIGH</sup> mice to a tail transection assay. Elevated hematocrit did not shorten the clotting time under normal conditions, likely due to the already very short clotting time (median ~88 sec). However, when mice were infused with heparin to prolong the clotting time, RBC<sup>HIGH</sup> mice had a shorter clotting time than control mice ( $P < 0.05$ , Figure 2D). Together, data from these two models suggest elevated hematocrit accelerates clot formation *in vivo*.

**Thrombi from control and RBC<sup>HIGH</sup> mice do not differ in size or fibrin content.** To determine how elevated hematocrit accelerates thrombosis, we first excised the occluded carotid artery from a subset of mice subjected to FeCl<sub>3</sub> injury. Both control and RBC<sup>HIGH</sup> mice had fully occlusive thrombi that were similar in size (Figure 3A,B). Thrombi from both control and RBC<sup>HIGH</sup> mice were primarily composed of proteinaceous material with sparse, small islands of RBCs, and showed similar fibrin staining (amount and intensity, Figure 3A). These data suggest elevated hematocrit does not increase thrombus size or fibrin content.

**Thrombin generation does not differ in control and RBC<sup>HIGH</sup> mice *in vivo*.** We then tested the hypothesis that RBC<sup>HIGH</sup> mice had enhanced activation of coagulation following FeCl<sub>3</sub> injury. We drew blood from mice 5 min after artery occlusion and measured TATc in plasma. TATc were similar in control and RBC<sup>HIGH</sup> mice ( $7.1 \pm 2.8$  and  $9.8 \pm 5.3$  ng/mL, respectively, mean  $\pm$  SD,  $P = 0.32$ , Figure 3C), and circulating TATc levels did not correlate with hematocrit (Figure 3D). These data suggest elevated levels of normal RBCs do not promote thrombus formation by increasing thrombin generation.

**Effect of RBCs thrombin generation depends on the platelet concentration.** The observation that RBC<sup>HIGH</sup> mice did not have increased circulating TATc suggested elevated RBCs did not augment thrombin generation during arterial thrombosis in mice. To examine the relative contribution of RBCs and platelets to thrombin generation, we isolated and then reconstituted plasma, platelets, and RBCs from healthy humans to levels indicated in Figure 4. We then triggered coagulation with tissue factor and recalcification and measured thrombin generation by whole blood calibrated automated thrombography. In the absence of platelets, increasing hematocrit increased the thrombin generation rate, peak, and endogenous thrombin potential (Figure 4, Table II). This finding is consistent with prior studies<sup>12,13,15</sup>, and is thought to reflect prothrombin cleavage on the surface of phosphatidylserine-

expressing RBCs.<sup>12</sup> However, in reactions with  $200 \times 10^6$  platelets/mL, hematocrit had less effect on thrombin generation (Figure 4, Table II), and in reactions with  $450 \times 10^6$  platelets/mL, there was no effect of hematocrit on thrombin generation (Figure 4, Table II). Increased thrombin generation was detected in control reactions with elevated prothrombin (data not shown), indicating the lack of increased thrombin detected was not due to fluorogenic substrate consumption. Together with the lack of increased circulating TATc in RBC<sup>HIGH</sup> mice (Figure 3C), these data suggest that in mice and humans with normal or elevated platelet levels, normal RBCs do not enhance thrombin generation during arterial thrombus formation.

**A computational model suggests elevated hematocrit increases the time that platelets spend in proximity to a thrombus.** Direct numerical simulations of RBCs and platelets near a porous thrombus show RBCs strongly influence platelet motion and orientation.<sup>37</sup> Since arterial thrombi are platelet-rich, we then tested the hypothesis that the prothrombotic effect of elevated hematocrit was mediated by enhanced interactions of flowing platelets with the thrombus. We conducted *in silico* simulations of whole blood flow at 40 and 60% hematocrit, in both the absence and presence of small and large porous thrombi. Comparisons with and without thrombi enabled us to evaluate effects of interstitial velocity on platelet behavior.

Figure 5A-D shows the instantaneous configuration and time-averaged distribution of RBCs and platelets resulting from simulations at 40 and 60% hematocrit. These data reveal a zone along a straight wall in which RBC concentrations were reduced and platelet concentrations were enhanced, and that this near-wall zone was narrower for 60% than 40% hematocrit (Figure 5A,B). The zone's width was also smaller for 60% than 40% hematocrit both upstream of (1.0 versus 3.0  $\mu\text{m}$ , respectively) and over (0.28 versus 1.28  $\mu\text{m}$ , respectively) a small thrombus (Figures 5C,D). Results were similar in simulations with larger thrombi (data not shown). This decreased near-wall zone resulted from increased interstitial velocity within the porous thrombus versus the solid wall. Narrowing of this zone pushed platelets close to the thrombi, so that platelets spent more time in proximity to the thrombus than to a comparable segment of flat vessel wall; i.e., at 40% hematocrit, for the same trajectory length (44  $\mu\text{m}$ ), platelets spent 11.5 msec within 0.5  $\mu\text{m}$  of the porous thrombus versus only 3.1 msec near the solid wall.

Figure 5E-H shows a sequence of snapshots every 2 msec of a representative platelet's position near small (Figure 5E,F) and large (Figure 5G,H) thrombi. For the small thrombus, the average time the platelet spent within 0.5  $\mu\text{m}$  of the thrombus was greater for 60% hematocrit than 40% hematocrit

( $29.5 \pm 26.6$  msec versus  $11.5 \pm 10.0$  msec, respectively, mean $\pm$ SD). Trends for the larger thrombus were similar, but interactions were even longer and showed a greater difference between hematocrits ( $41.0 \pm 39.4$  versus  $15.4 \pm 9.5$  msec, mean $\pm$ SD). Consistent with previous studies<sup>37</sup>, interactions in both cases were particularly frequent and prolonged near the upstream face of the thrombus. A linear fit of mean platelet interaction times with the small thrombus for 40% and 60% hematocrits predicts an increase of ~55% in the mean interaction time for a 47% hematocrit. The analogous calculation for the large thrombus predicts an increase of 58%. These predicted values from the simulations agree well with the 67% increase in mean thrombus growth rate observed *in vivo* for 47% versus 40% hematocrit. Together, these data suggest elevated hematocrit enhances platelet contact with a thrombus in flowing blood, and that the frequency of these interactions increases with thrombus growth.

**Elevated hematocrit increases the rate of platelet accumulation on collagen at an arterial shear rate.** Finally, to directly compare the effect of hematocrit on fibrin formation and platelet accumulation, we used an *in vitro* microfluidic model to visualize and measure thrombus growth on 200- $\mu$ m collagen spots at an arterial shear rate ( $750 \text{ sec}^{-1}$ ). Consistent with the *in vivo* findings and predictions from *in silico* simulations, elevated hematocrit significantly accelerated thrombus growth (Figure 6A,B), exposing a direct, prothrombotic effect of increased hematocrit on thrombus formation. The sensitivity of these *in vitro* experiments to very early thrombus formation also revealed a small, but significant, shortening of the lag time to thrombus initiation that was not detectable in the *in vivo* experiments. This reduction in lag time is consistent with *in silico* predictions of enhanced margination at higher hematocrit near a straight, non-porous wall (Figure 5A,B). There was no measurable effect of hematocrit on fibrin deposition (data not shown), consistent with *in vivo* and *in vitro* findings indicating little-to-no effect of elevated hematocrit on thrombin generation or fibrin formation at normal platelet counts. Notably, however, Figure 6C illustrates a moderate, though significant, effect of hematocrit on the rate of platelet accumulation in the thrombus. This finding is consistent with predictions from the computational model suggesting elevated hematocrit increases the frequency and duration of platelet-thrombus interactions, and therefore, the likelihood that these interactions will result in platelet accumulation in the thrombus. Collectively, these data suggest elevated hematocrit promotes platelet interactions with a forming thrombus, leading to faster platelet accumulation and accelerated thrombus growth.

## DISCUSSION

Although RBCs have procoagulant properties *in vitro*, effects of RBCs on thrombosis *in vivo* are difficult to assess because humans and mice with elevated hematocrit typically have co-existing pathologies. Herein, we used an experimental model of elevated hematocrit in healthy mice and showed these mice have accelerated arterial thrombus formation and a shortened tail transection clotting time. Elevated hematocrit did not enhance thrombin generation or fibrin deposition *in vivo* or *in vitro* in the presence of normal numbers of platelets. However, elevated hematocrit increased the frequency of platelet interactions with thrombi *in silico*, and accelerated the rate of platelet accumulation in thrombi in a microfluidic-based model of thrombus formation. Collectively, these findings suggest RBCs independently promote arterial thrombosis and show this occurs via a platelet-dependent increase in thrombus growth.

Epidemiologic studies of healthy humans associate elevated hematocrit with thrombosis, and suggest increased risk exists at even moderately-elevated baseline hemoglobin/hematocrit levels. In a large prospective cohort analysis (>8,000 subjects), incidence of myocardial infarction (MI), coronary insufficiency, or coronary heart disease deaths was more than double in individuals with high hematocrit (>49%) compared to individuals with low hematocrit (<42%).<sup>19</sup> Likewise, the Framingham study followed >5,000 men and women (30-62 years old) over 34 years and showed that compared to individuals in the mid-hematocrit quintile, young men and women in the highest quintile (men  $\geq$ 49%, women  $\geq$ 46%) had an increased risk of death from cardiovascular disease.<sup>21</sup> Similarly, in the British Regional Heart Study involving >7,700 men, risk of major ischemic heart disease events was increased by 30% at hematocrit >46%, compared to those below this cut-off.<sup>22</sup> Additional longitudinal studies of young men showed that a high hematocrit at baseline was associated with 1.4-to-1.9-fold increased risk of MI during the follow-up period.<sup>20,24</sup> In most of these studies, the association with thrombosis was independent of other cardiovascular risk factors, including smoking, itself a recognized cause of elevated hematocrit.

Increased hematocrit has also been implicated in thrombosis associated with a number of erythrocytotic disorders including PV, Chuvash polycythemia, and erythropoietin-induced erythrocytosis. In PV, risk of cardiovascular death and major thrombosis is significantly reduced by maintaining the hematocrit <45%, compared to 45-50%.<sup>42</sup> However, determining specific prothrombotic effects of hematocrit in these patients is complicated by the underlying disease pathophysiology.

Together with older studies, our findings provide biophysical mechanisms that may explain these observations: elevated hematocrit increases the duration and frequency of platelet-thrombus interactions. In contrast to most computational studies of margination in long, straight tubes<sup>35,43-46</sup>, our model includes the perturbation of blood flow by a thrombus penetrating into the lumen. Importantly, like thrombi *in vivo*<sup>47</sup>, the thrombi in our *in silico* model are porous, allowing for interstitial flow through the thrombus interior. The magnitude of interstitial flow increases with hematocrit, ultimately pushing platelets closer to the surface, while reducing tumbling. As a result, platelets are in close proximity to the thrombus for longer times, increasing the probability of receptor-ligand bond formation. Related *in silico* studies show that even at a hematocrit of 10%, RBCs enhance platelet deposition in stenosed vessels, in part by reducing the distance between a platelet and a non-porous thrombus.<sup>48</sup> Effects of elevated hematocrit on platelet accumulation in our assays were significant but moderate, consistent with the moderately increased risk observed in epidemiologic studies.<sup>19-21,24</sup> Notably, the premise that elevated hematocrit promotes thrombosis via platelet-dependent mechanisms is consistent with clinical findings that platelet antagonism reduces cardiovascular death, non-fatal MI, and stroke in patients with PV.<sup>49</sup> Thus, these data may provide rationale for the efficacy of platelet inhibition strategies in patients with elevated hematocrit and increased thrombosis risk.

Since RBCs can support thrombin generation<sup>12-15</sup>, the observation that elevated hematocrit did not increase circulating TATc was somewhat surprising. However, the dependence of arterial thrombosis on platelet function<sup>50</sup> and scarcity of RBCs in the thrombus (Figure 3A) suggest phosphatidylserine expressed by normal RBCs does not substantively augment local thrombin generation during arterial thrombosis. However, RBCs may enhance thrombin generation in certain clinical situations. For example, patients with thrombocytopenia<sup>51</sup> or increased numbers of circulating phosphatidylserine-positive RBCs (e.g., sickle cell disease,  $\beta$ -thalassemia, or PV)<sup>40,52-55</sup> may demonstrate clinically-meaningful, RBC-mediated thrombin generation. Indeed, in patients with sickle cell disease, numbers of circulating phosphatidylserine-positive RBCs correlate with circulating prothrombin fragment 1.2.<sup>52</sup> In addition, RBCs may support thrombin generation in venous thrombi, where the RBC content is higher than in arterial thrombi. Further studies are warranted to evaluate the effects of elevated hematocrit in these situations. Our approach to raise the hematocrit in mice with RBCs harvested from other mice is exploitable for investigating these situations, as well as the effect of RBCs with biophysical and/or biochemical abnormalities, including sickled RBCs, in future studies.

This study has potential limitations. First, mice differ from humans in vascular dimensions, size of RBCs and platelets, number of platelets, and blood rheology. However, our data demonstrate consistent, prothrombotic effects of elevated hematocrit in both murine and human experimental systems. Second, although FeCl<sub>3</sub> is a common agent for inducing thrombosis in animal models, ferric ions cause charge-suppression of plasma proteins and blood cells leading to initial adhesion of blood cells, including RBCs, to the endothelium by non-biological mechanisms.<sup>56-60</sup> However, subsequent propagation of thrombus into the vessel lumen, including platelet accumulation and thrombus growth, is still thought to recapitulate key aspects of arterial thrombus formation.<sup>57,60</sup> Moreover, results were supported by independent experimental systems *in vivo* (tail transection), *in silico* (simulation), and *in vitro* (microfluidics). Third, our findings are limited to mildly elevated hematocrit. In future studies, it may be useful to examine the relationship between hematocrit and thrombosis across a broader range. Such studies may identify a non-linear, and even J-shaped<sup>21</sup>, response to hematocrit. For example, in situations where hematocrit elevation is extreme such as in patients with cyanotic congenital heart disease, hyperviscosity may paradoxically manifest as a bleeding tendency<sup>61</sup>, an association that can also be seen in mice with extremely high hematocrits<sup>26</sup>. Thus, the relationship between thrombosis and elevated hematocrit/hemoglobin may be complex and dependent on the mechanism and degree of erythrocytosis. Finally, our study does not address potential effects of chronically-elevated hematocrit, in which additional systemic effects may also impact thrombosis.

In summary, our data suggest elevated hematocrit promotes arterial thrombosis. Effects are independent of thrombin generation, but associated with accelerated platelet accumulation within the thrombus. These findings suggest maintaining a normal hematocrit or reducing platelet function in patients with elevated hematocrit may reduce arterial thrombosis risk.

## **ACKNOWLEDGEMENTS**

The authors thank Dr. Erica Sparkenbaugh for advice, James R. Byrnes for reading the manuscript, and Kenzie S. McConnell for assistance with data processing.

## **AUTHORSHIP**

Contributions: B.L.W. designed and performed experiments, analyzed and interpreted the data, and wrote the manuscript; M.L., T.S., L.A.H., J.D.B., J.A.C., M.J.M., A.R.W. and B.C.C. performed experiments and analyzed and interpreted the data; R.P. designed experiments; J.W.H. and M.R.F. analyzed and interpreted the data; N.S.K., A.L.F., K.B.N., and A.S.W. designed the research, analyzed and interpreted the data, and wrote the manuscript. All authors reviewed and approved the manuscript.

Conflict-of-interest: The authors declare no competing financial interests.

## **FUNDING**

This study was supported by funding from the National Institutes of Health (R56HL094740 and R01HL126974 to A.S.W., 1UL1TR001111 to NC TraCS/A.S.W., T32HL069768 and T32HL007149 to the University of North Carolina, R01HL120728 to K.B.N. and A.L.F., and R01HL126864 to A.L.F.), National Science Foundation CAREER Award (CBET-1351672 to K.B.N.) and grant (DMS-1521748 to A.L.F.), American Heart Association (14GRNT20410094 to K.B.N.), and by the National Center for Advancing Translational Sciences (NCATS).



## REFERENCES

1. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. *Br J Haematol*. 1997;96:168-173.
2. Pries AR, Neuhaus D, Gaehtgens P. Blood viscosity in tube flow: dependence on diameter and hematocrit. *Am J Physiol*. 1992;263:H1770-1778.
3. Merrill EW. Rheology of Blood. *Physiological Reviews*. 1969;49:863-888.
4. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. *Semin Thromb Hemost*. 2003;29:451-458.
5. Grabowski EF, Yam K, Gerace M. Evaluation of hemostasis in flowing blood. *Am J Hematol*. 2012;87 Suppl 1:S51-55.
6. Fogelson AL, Neeves KB. Fluid mechanics of blood clot formation. *Annu Rev Fluid Mech*. 2015;47:377-403.
7. Silvain J, Pena A, Cayla G, et al. Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. *Eur Heart J*. 2010;31:2816-2821.
8. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. *J Clin Invest*. 1991;87:571-580.
9. Valles J, Santos MT, Aznar J, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. *Blood*. 2002;99:3978-3984.
10. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. *Science*. 1980;207:541-543.
11. Kuypers FA, Lewis RA, Hua M, et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. *Blood*. 1996;87:1179-1187.
12. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. *Blood*. 2012;120:3837-3845.
13. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pflieger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. *Thromb Haemost*. 1999;81:400-406.

14. Horne MK, 3rd, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. *Br J Haematol*. 2006;133:403-408.
15. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. *Clin Chem*. 2012;58:1252-1259.
16. van Beers EJ, Schaap MC, Berckmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. *Haematologica*. 2009;94:1513-1519.
17. Rubin O, Delobel J, Prudent M, et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. *Transfusion*. 2013;53:1744-1754.
18. Mooberry MJ, Bradford R, Hobl EL, Lin FC, Jilma B, Key NS. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. *J Thromb Haemost*. 2016;14:1031-1042.
19. Sorlie PD, Garcia-Palmieri MR, Costas R, Jr., Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. *Am Heart J*. 1981;101:456-461.
20. Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Haematocrit: a predictor of cardiovascular mortality? *J Intern Med*. 1993;234:493-499.
21. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. *Am Heart J*. 1994;127:674-682.
22. Wannamethee G, Shaper AG, Whincup PH. Ischaemic heart disease: association with haematocrit in the British Regional Heart Study. *Journal of epidemiology and community health*. 1994;48:112-118.
23. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. *Circulation*. 2005;111:2042-2049.
24. Toss F, Nordstrom A, Nordstrom P. Association between hematocrit in late adolescence and subsequent myocardial infarction in Swedish men. *Int J Cardiol*. 2013;168:3588-3593.
25. Paffett-Lugassy N, Hsia N, Fraenkel PG, et al. Functional conservation of erythropoietin signaling in zebrafish. *Blood*. 2007;110:2718-2726.
26. Shibata J, Hasegawa J, Siemens HJ, et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. *Blood*. 2003;101:4416-4422.
27. Lamrani L, Lacout C, Ollivier V, et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. *Blood*. 2014;124:1136-1145.

28. Strassel C, Kubovcakova L, Mangin PH, et al. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. *Thromb Haemost.* 2015;113:414-425.
29. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. *J Exp Med.* 2013;210:205-208.
30. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. *Kidney international.* 2006;70:246-250.
31. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. *J Exp Med.* 2010;207:2831-2842.
32. Hand CC, Brines M. Promises and pitfalls in erythropoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? *Journal of investigative medicine : the official publication of the American Federation for Clinical Research.* 2011;59:1073-1082.
33. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. *Blood.* 2011;117:4953-4963.
34. Walton BL, Getz TM, Bergmeier W, Lin F-C, Uitte de Willige S, Wolberg AS. The fibrinogen gammaA/gamma' isoform does not promote acute arterial thrombosis in mice. *J Thromb Haemost.* 2014;12:680-689.
35. Crowl L, Fogelson AL. Analysis of mechanisms for platelet near-wall excess under arterial blood flow conditions. *J Fluid Mech.* 2011;676:348-375.
36. Crowl LM, Fogelson AL. Computational model of whole blood exhibiting lateral platelet motion induced by red blood cells. *International journal for numerical methods in biomedical engineering.* 2010;26:471-487.
37. Skorzewski T, Erickson LC, Fogelson AL. Platelet motion near a vessel wall or thrombus surface in two-dimensional whole blood simulations. *Biophys J.* 2013;104:1764-1772.
38. Rana K, Timmer BJ, Neeves KB. A combined microfluidic-microstencil method for patterning biomolecules and cells. *Biomicrofluidics.* 2014;8:056502.
39. Lehmann M, Wallbank AM, Dennis KA, et al. On-chip recalcification of citrated whole blood using a microfluidic herringbone mixer. *Biomicrofluidics.* 2015;9:064106.
40. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. *Blood.* 1996;88:1873-1880.

41. Gilson CR, Kraus TS, Hod EA, et al. A novel mouse model of red blood cell storage and posttransfusion in vivo survival. *Transfusion*. 2009;49:1546-1553.
42. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med*. 2013;368:22-33.
43. Kumar A, Graham MD. Mechanism of margination in confined flows of blood and other multicomponent suspensions. *Phys Rev Lett*. 2012;109:108102.
44. Reasor DA, Jr., Mehrabadi M, Ku DN, Aidun CK. Determination of critical parameters in platelet margination. *Ann Biomed Eng*. 2013;41:238-249.
45. Zhao H, Shaqfeh ES. Shear-induced platelet margination in a microchannel. *Physical review E, Statistical, nonlinear, and soft matter physics*. 2011;83:061924.
46. Vahidkhan K, Diamond SL, Bagchi P. Platelet dynamics in three-dimensional simulation of whole blood. *Biophys J*. 2014;106:2529-2540.
47. Stalker TJ, Welsh JD, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. *Blood*. 2014;124:1824-1831.
48. Wang W, Diacovo TG, Chen J, Freund JB, King MR. Simulation of platelet, thrombus and erythrocyte hydrodynamic interactions in a 3D arteriole with in vivo comparison. *PLoS One*. 2013;8:e76949.
49. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med*. 2004;350:114-124.
50. Ruggeri ZM. Platelets in atherothrombosis. *Nat Med*. 2002;8:1227-1234.
51. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch Intern Med*. 2008;168:2377-2381.
52. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. *Blood*. 2001;98:3228-3233.
53. Fujita H, Sakuma R, Tomiyama J, et al. Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. *Br J Haematol*. 2011;152:238-240.
54. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. *Am J Hematol*. 1993;44:63-65.

55. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. *Blood*. 2003;102:365-370.
56. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. *Blood*. 2013;121:3733-3741.
57. Ciciliano JC, Sakurai Y, Myers DR, et al. Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. *Blood*. 2015;126:817-824.
58. Woollard KJ, Sturgeon S, Chin-Dusting JP, Salem HH, Jackson SP. Erythrocyte hemolysis and hemoglobin oxidation promote ferric chloride-induced vascular injury. *J Biol Chem*. 2009;284:13110-13118.
59. Schoenwaelder SM, Jackson SP. Ferric chloride thrombosis model: unraveling the vascular effects of a highly corrosive oxidant. *Blood*. 2015;126:2652-2653.
60. Neeves KB. Physiochemical artifacts in FeCl<sub>3</sub> thrombosis models. *Blood*. 2015;126:700-701.
61. Jensen AS, Johansson PI, Idorn L, et al. The haematocrit--an important factor causing impaired haemostasis in patients with cyanotic congenital heart disease. *Int J Cardiol*. 2013;167:1317-1321.

**TABLES****I. Complete blood counts in mice**

	Normal Range	Control	RBC <sup>HIGH</sup>	P Value*
Hematocrit (%)	35.1 – 45.4	39.3 ± 0.7	46.6 ± 0.7	<0.0001
Neutrophils (x10 <sup>6</sup> /mL)	0.1 – 2.4	1.1 ± 0.3	1.7 ± 0.4	0.15
Monocytes (x10 <sup>6</sup> /mL)	0.0 – 0.4	0.3 ± 0.1	0.2 ± 0.0	0.16
Platelets (x10 <sup>6</sup> /mL)	592 – 2972	802 ± 33	699 ± 33	0.04

Data show mean±SD. \*Student's *t*-test

**II. Thrombin generation in reconstituted human whole blood**

Hematocrit:	No platelets			200x10 <sup>6</sup> /mL platelets			450x10 <sup>6</sup> /mL platelets		
	0%	20%	45%	0%	20%	45%	0%	20%	45%
Lagtime (min)	9.1±5.2	9.8±2.0	12.9±1.7	7.2±1.0	7.3±1.2	7.4±0.6	7.4±1.0	6.9±0.8	7.2±1.3
Time to Peak (min)	23.8±10.0	14.2±2.0	18.7±2.7	13.2±1.7	11.2±1.6	11.2±1.0	12.5±1.4	10.9±1.2	11.0±1.7
Rate (nM/min)	0.2±0.1	4.7±0.5*	6.4±1.1*	3.0±0.2	5.4±1.0*	8.5±1.7*	3.7±1.9	6.1±0.4	6.5±1.1
Peak (nM)	3.9±2.0	51.8±7.3*	74.3±23.0*	42.9±2.9	63.2±17.1*	84.0±30.0*	65.8±34.9	64.1±5.4	69.1±15.9
ETP (nM*min)	51.0±50.5	382.3±74.9*	619.3±209.9*	418.8±59.9	412.0±149.5	525.2±197.8	500.8±261.1	414.0±43.8	457.5±122.2

Thrombin generation was measured by whole blood calibrated automated thrombography. Data show mean±SD. *N*=3-6 separate experiments per condition. \*ANOVA with Dunnet's post-hoc test, *P*<0.05 versus 0% hematocrit for each platelet concentration.

## FIGURES

**Figure 1. Model of elevated hematocrit in mice.** RBCs from “donor” mice were injected into “recipient” mice (RBC<sup>HIGH</sup>) via retro-orbital plexus. After 24 hours, blood was drawn from RBC<sup>HIGH</sup> and control (un-infused) mice. Complete cell counts indicate (A) elevated hematocrit, but normal (B) neutrophil, (C) monocyte, and (D) platelet numbers. In A-D each dot is a separate mouse, lines indicate median values, and boxes represent the normal range. (E) Blood smears of washed RBCs and whole blood from control and RBC<sup>HIGH</sup> mice indicate normal RBC morphology. (F) Flow cytometry indicates normal phosphatidylserine exposure on washed RBCs and RBCs isolated from control and RBC<sup>HIGH</sup> mice. Bars indicate mean±SD, *N*=3. (G) Viscosity measurements show RBC<sup>HIGH</sup> mice (closed circles) have significantly increased viscosity (Pascal-seconds, Pa.s) at low and high shear compared to control mice (open circles). Symbols show mean±SD, *N*=3-5/group.

**Figure 2. Compared to control mice, RBC<sup>HIGH</sup> mice have a shortened time to vessel occlusion.** (A-D) Control and RBC<sup>HIGH</sup> mice were subjected to FeCl<sub>3</sub>-induced carotid artery thrombosis. (A) Time to vessel occlusion. When vessels did not occlude, time to occlusion was recorded as 20 min (3 control mice). (B) Onset and (C) rate of thrombus formation in control (un-infused) and RBC<sup>HIGH</sup> mice. (D) Control and RBC<sup>HIGH</sup> mice were treated with saline (baseline) or heparin and then subjected to tail transection. Each dot or box is a separate mouse, boxes with stars represent mice that did not form clots. Lines indicate median values, Wilcoxon 1-tailed comparison.


**Figure 3. Following FeCl<sub>3</sub> injury, control and RBC<sup>HIGH</sup> mice have similar thrombus morphology and similar levels of circulating thrombin-antithrombin complexes (TATc).** (A-B) Thrombi from a subset of mice subjected to FeCl<sub>3</sub>-induced carotid artery thrombosis were excised, fixed in 10% formalin, transferred to 70% ethanol, and analyzed. (A) Hematoxylin and eosin (H&E) staining (upper panels) and immunohistochemistry for fibrin (brown staining, lower panels). Scale bars indicate 500 μm. (B) Thrombus size was determined by measuring pixel area of the thrombus within the vessel. (C) TATc were measured by ELISA in plasmas from control (un-infused) and RBC<sup>HIGH</sup> mice following FeCl<sub>3</sub>-induced artery occlusion. (D) Relationship between hematocrit and TATc levels measured after FeCl<sub>3</sub>-induced artery occlusion in control (open circles) and RBC<sup>HIGH</sup> (closed circles) mice. In B-D, each dot is a separate mouse. In B-C, horizontal lines indicate medians.


**Figure 4. The effect of RBCs on thrombin generation depends on the endogenous platelet concentration.** Thrombin generation in reconstituted whole blood with varying hematocrit (HCT) and platelets (Plts) was analyzed by calibrated automated thrombography. Hematocrits above 45% interfered with the thrombin generation assay and could not be measured reproducibly.  $N=3-6$  per condition, bars represent mean peak thrombin $\pm$ SD. \* $P<0.05$ , \*\* $P<0.005$ .





**Figure 5. A computational model suggests elevated hematocrit increases the time that platelets spend in proximity to a thrombus.** Simulations of whole blood flow with 40% (A, C, E, G) and 60% (B, D, F, H) hematocrit were conducted as described in Methods. (A-B) Snapshots showing instantaneous positions of RBCs (red) and platelets (black) for (A) 40% and (B) 60% hematocrit in flowing blood indicate RBCs are less prevalent close to vessel walls and platelets are more prevalent in this near-wall RBC-depleted zone. (C-D) Time-average RBC distribution for flow past a small thrombus (filled circles) in (C) 40% and (D) 60% hematocrit. The near-wall depleted zone is narrower in higher hematocrit. Scale indicates relative RBC distribution. (E-H) Time-dependent progression (2-msec intervals) of an individual platelet (blue) over a small or large thrombus (black circles): (E) 40% hematocrit, small thrombus, (F) 60% hematocrit, small thrombus, (G) 40% hematocrit, large thrombus, (H) 60% hematocrit, large thrombus. For both the small and large thrombus, the platelet spends substantially more time near the thrombus for 60% hematocrit than for 40% hematocrit. Bars indicate 10  $\mu$ m.


**Figure 6. Elevated hematocrit increases the rate of platelet accumulation on collagen at an arterial shear rate.** Reconstituted whole blood was perfused over type I collagen at  $750 \text{ sec}^{-1}$ . (A) Representative images of thrombus surface coverage and platelet fluorescence 1.5 min after initiation of flow. Scale bar indicates 50  $\mu$ m. (B) Average thrombus area (normalized to collagen spot area as fractional surface coverage) and individual thrombus lag times and rates for all experiments. (C) Average platelet accumulation (integrated fluorescence intensity units [IFU] of DiOC6-labeled platelets) and individual platelet lag times and rates for all experiments.  $N=7$  independent donors per condition. Values show mean $\pm$ SD for 41% (open circles) and 54% (closed circles) hematocrit, lines indicate paired data for individual blood donors.

























**blood**<sup>®</sup>

Prepublished online March 1, 2017;  
doi:10.1182/blood-2016-10-746479

## **Elevated hematocrit enhances platelet accumulation following vascular injury**

Bethany L. Walton, Marcus Lehmann, Tyler Skorczewski, Lori A. Holle, Joan D. Beckman, Jeremy A. Cribb, Micah J. Mooberry, Adam R. Wufsus, Brian C. Cooley, Jonathan W. Homeister, Rafal Pawlinski, Michael R. Falvo, Nigel S. Key, Aaron L. Fogelson, Keith B. Neeves and Alisa S. Wolberg

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

---

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.